WO2000061183A3 - Verotoxin treatment of lymphomas - Google Patents

Verotoxin treatment of lymphomas Download PDF

Info

Publication number
WO2000061183A3
WO2000061183A3 PCT/CA2000/000371 CA0000371W WO0061183A3 WO 2000061183 A3 WO2000061183 A3 WO 2000061183A3 CA 0000371 W CA0000371 W CA 0000371W WO 0061183 A3 WO0061183 A3 WO 0061183A3
Authority
WO
WIPO (PCT)
Prior art keywords
verotoxin
lymphomas
treatment
lymphoma
ptld
Prior art date
Application number
PCT/CA2000/000371
Other languages
French (fr)
Other versions
WO2000061183A2 (en
Inventor
Clifford A Lingwood
Gerald Arbus
Original Assignee
Hsc Res Dev Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hsc Res Dev Lp filed Critical Hsc Res Dev Lp
Priority to AU37985/00A priority Critical patent/AU3798500A/en
Publication of WO2000061183A2 publication Critical patent/WO2000061183A2/en
Publication of WO2000061183A3 publication Critical patent/WO2000061183A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for treating lymphoma by the administration of an agent that binds Gb3 are disclosed. In one embodiment, the lymphoma may be, for example, PTLD.
PCT/CA2000/000371 1999-04-09 2000-04-07 Verotoxin treatment of lymphomas WO2000061183A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU37985/00A AU3798500A (en) 1999-04-09 2000-04-07 Verotoxin treatment of lymphomas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12867099P 1999-04-09 1999-04-09
US60/128,670 1999-04-09

Publications (2)

Publication Number Publication Date
WO2000061183A2 WO2000061183A2 (en) 2000-10-19
WO2000061183A3 true WO2000061183A3 (en) 2001-02-08

Family

ID=22436415

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000371 WO2000061183A2 (en) 1999-04-09 2000-04-07 Verotoxin treatment of lymphomas

Country Status (2)

Country Link
AU (1) AU3798500A (en)
WO (1) WO2000061183A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002349228B2 (en) * 2001-11-30 2007-06-14 National Research Council Of Canada Self-assembly molecules
EP1386927B1 (en) 2002-08-02 2005-03-30 Institut Curie Shiga toxin B-subunit as a vector for tumor diagnosis and drug delivery to GB3 expressing tumors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0130132A1 (en) * 1983-06-27 1985-01-02 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Antitumour immunotoxin, pharmaceutical compositions containing it, and its use in vitro
WO1995022349A1 (en) * 1994-02-22 1995-08-24 Geva, Ruth Verotoxin pharmaceutical compositions and medical treatments therewith
WO1998051326A1 (en) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition of angiogenesis by verotoxins

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0130132A1 (en) * 1983-06-27 1985-01-02 Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) Antitumour immunotoxin, pharmaceutical compositions containing it, and its use in vitro
WO1995022349A1 (en) * 1994-02-22 1995-08-24 Geva, Ruth Verotoxin pharmaceutical compositions and medical treatments therewith
WO1998051326A1 (en) * 1997-05-16 1998-11-19 Hsc Research And Development Limited Partnership Inhibition of angiogenesis by verotoxins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ARBUS GERALD S ET AL: "Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease.", LEUKEMIA RESEARCH, vol. 24, no. 10, October 2000 (2000-10-01), pages 857 - 864, XP000960973, ISSN: 0145-2126 *
LACASSE E C ET AL: "SHIGA-LIKE TOXIN PURGES HUMAN LYMPHOMA FROM BONE MARROW OF SEVERE COMBINED IMMUNODEFICIENT MICE", BLOOD,US,W.B. SAUNDERS, PHILADELPHIA, VA, vol. 88, no. 5, 1 September 1996 (1996-09-01), pages 1561 - 1567, XP000673518, ISSN: 0006-4971 *
MANGENEY MARIANNE ET AL: "Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen.", CANCER RESEARCH, vol. 53, no. 21, 1993, pages 5314 - 5319, XP002030860, ISSN: 0008-5472 *
RANDHAWA P S ET AL: "Morphologic and immunophenotype characterization of a cell line derived from liver tissue with Epstein-Barr virus associated post-transplant lymphoproliferative disease.", IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL, vol. 30A, no. 6, 1994, pages 400 - 406, XP000960975, ISSN: 1071-2690 *

Also Published As

Publication number Publication date
AU3798500A (en) 2000-11-14
WO2000061183A2 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
MXPA02010801A (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites.
IL147618A0 (en) Method for treating chronic pain using mek inhibitors
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
PL352021A1 (en) Agent having advantageous effect on ketose
PT1355889E (en) SUBSTITUTED DIAMINE TRIAZOLE DERIVATIVES AS KINASE INHIBITORS
FR13C0062I1 (en)
EP2230254A3 (en) Anti-IGFR1 antibody therapeutic combinations
EP0781136A4 (en) Compounds and methods for the treatment of cancer
AU5540400A (en) Bicyclic polyaminoacid metal complexes, method for preparing same and use in medical imaging
MX2007009908A (en) Methods for treating lymphomas using a combination of a chemotherapeutic agent and il-2 and optionally an anti-cd20 antibody.
AU2003297318A1 (en) Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
HK1043603A1 (en) Hard surface treating agent, stain-proofing agent and method for surface treatment.
WO2002055530A3 (en) Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
MXPA01010988A (en) Use of macrolide compounds for the treatment of dry eye.
WO2003082926A3 (en) Antimicrobial polymer conjugates
WO2000061183A3 (en) Verotoxin treatment of lymphomas
EP1235622A4 (en) Electrodeionization substrate, and device for electrodeionization treatment
IL161600A0 (en) Compounds and method for the treatment of over-active bladder
TR200103219T2 (en) Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain
IL148336A0 (en) Medicaments that contain xenogenic oligo-or/and polyribonucleotides
IL164356A (en) Use of alpha- bromo or alpha-chloro acryloyl distamycin derivatives in the preparation of medicaments for treating cancer
WO2004006866A3 (en) Antifungal therapeutic targets
UA32303A (en) Method for treating papillomatosis
UA32363A (en) Method for treating chronic alcoholism
AU2002224431A1 (en) 2-substituted heterocyclic compounds and their use in treating multidrug resistance

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP